About BioGenomics
BioGenomics is a company based in Thane (India) founded in 2002 by Archana Krishnan and Sanjay Sonar. BioGenomics has raised $24.62 million across 2 funding rounds from investors including Oman Investment Authority and Eagle Asia Holding. The company has 193 employees as of December 02, 2024. BioGenomics offers products and services including Biopharmaceuticals and Recombinant Proteins. BioGenomics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Thane, India
- Employees 193 as on 02 Dec, 2024
- Founders Archana Krishnan, Sanjay Sonar
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biogenomics Limited
- Date of Incorporation 24 Apr, 2002
- Jurisdiction Pondicherry, Pondicherry, India
-
Annual Revenue
$1.57 M (USD)0as on Mar 31, 2024
-
Net Profit
-$2.8 M (USD)0as on Mar 31, 2024
-
EBITDA
-$3.08 M (USD)0as on Mar 31, 2024
-
Total Equity Funding
$24.62 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Oman Investment Authority
& 1 more
-
Employee Count
193
as on Dec 02, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of BioGenomics
BioGenomics offers a comprehensive portfolio of products and services, including Biopharmaceuticals and Recombinant Proteins.
Develops drugs targeting diabetes and cancer treatments effectively.
Produces proteins for medical applications and research purposes.
People of BioGenomics
Unlock access to complete
Funding Insights of BioGenomics
BioGenomics has successfully raised a total of $24.62M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in BioGenomics
BioGenomics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Oman Investment Authority and Eagle Asia Holding.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
National investments are managed by the Oman Investment Authority.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for BioGenomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioGenomics
Investment portfolio details for BioGenomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - BioGenomics
Detailed financials for BioGenomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biogenomics Comparisons
Peer comparison for BioGenomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioGenomics
BioGenomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of BioGenomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biogenomics
Complete news archive for BioGenomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioGenomics
BioGenomics was founded in 2002 and raised its 1st funding round 20 years after it was founded.
BioGenomics is headquartered in Thane, India. It is registered at Thane, Maharashtra, India.
Sanjay Sonar is the current CEO of BioGenomics. They have also founded this company.
BioGenomics is a funded company, having raised a total of $24.62M across 2 funding rounds to date.
As of Dec 02, 2024, the latest employee count at BioGenomics is 193.
Annual revenue of BioGenomics is $1.57M as on Mar 31, 2024.
BioGenomics was founded in 2002 in Thane, India, within the biotechnology sector. Recombinant DNA technology is utilized for biosimilars development, alongside recombinant proteins and enzymes. A platform for biosimilars is provided, including cell-culture reagents and enzymes that serve as replacements for animal-derived components. This enables production processes to be conducted without animal origins. Operations focus on these offerings to support biotech applications.
BioGenomics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
BioGenomics offers Biopharmaceuticals and Recombinant Proteins.
BioGenomics has 2 investors. Key investors include Oman Investment Authority, and Eagle Asia Holding.